Dexamethasone palmitate for patients with engraftment syndrome is associated with favorable outcome for children with hematological malignancy

Bone Marrow Transplant. 2016 Nov;51(11):1540-1542. doi: 10.1038/bmt.2016.178. Epub 2016 Jul 4.

Authors

H Sakaguchi¹, K Matsumoto², N Yoshida¹, K Narita¹, M Hamada¹, S Kataoka¹, N Miyagawa¹, T Yoshikawa³, M Ito⁴, K Kato¹

Affiliations

¹ Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
² Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
³ Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Japan.
⁴ Department of Pathology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.

PMID: 27376452
DOI: 10.1038/bmt.2016.178

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Child
Dexamethasone / administration & dosage*
Dexamethasone / analogs & derivatives
Female
Hematologic Neoplasms / complications
Hematologic Neoplasms / therapy*
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Immune System Diseases / chemically induced
Immune System Diseases / drug therapy
Immune System Diseases / etiology
Lymphohistiocytosis, Hemophagocytic / drug therapy
Macrophage Activation / drug effects*
Male
Palmitates / therapeutic use
Transplantation, Homologous / adverse effects
Treatment Outcome

Substances

Palmitates
dexamethasone 21-phosphate
Dexamethasone